Impact of long-term therapy with acetylsalicylic acid on immature platelet count: a single-centre cohort study
Authors:
- Federica NegroFNFederica Negro
- Roberta RollaRRRoberta Rolla
- 1 May 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 20 (5) , 306-312
Abstract
Acetylsalicylic acid (ASA) represents one of the most widely used pharmacological treatments for the prevention of atherothrombotic events. However, its use in low-risk patients is still debated, due to the complex balance between benefits and bleeding complications, therefore requiring new tools for the assessment of cardiovascular risk. Immature platelet count (IPC) has been suggested as a marker of platelet reactivity and turnover, thus potentially reflecting the progression of the chronic atherothrombotic vascular damage, which could be prevented by ASA. However, no study has evaluated, so far, the impact of long-term therapy with ASA on the IPC among patients undergoing coronary angiography, which was the aim of the present study. We included patients from a single centre. Significant coronary artery disease (CAD) was defined as at least one-vessel stenosis more than 50%. Immature platelet fraction (IPF) levels were measured by routine blood cells count (a Sysmex XE-2100) in patients naive or chronically treated with ASA at admission. Among 1475 patients, 464 (31.5%) were ASA-naive. Patients on long-term antiplatelet therapy were more often men (P < 0.001), with a higher prevalence of cardiovascular risk factors and CAD. The mean levels of IPC did not differ between ASA-naive and treated patents (8 ± 5.3 vs. 7.8 ± 4.9, P = 0.48). Similar results were obtained when considering IPC distribution across tertiles, as ASA therapy did not result as an independent predictor of IPC levels above the third tertile (≥8.6 × 106/ml) [adjusted odds ratio (95% confidence interval) = 0.96 (0.63–1.48), P = 0.87]. Results were confirmed in major higher risk subgroups of patients. The present study shows that among high-risk patients undergoing coronary angiography, the long-term therapy with ASA does not affect the levels of IPC.Keywords
This publication has 44 references indexed in Scilit:
- Antiplatelet agents for the treatment and prevention of atherothrombosisEuropean Heart Journal, 2011
- Impact of In-Hospital Major Bleeding on Late Clinical Outcomes After Primary Percutaneous Coronary Intervention in Acute Myocardial InfarctionJACC, 2011
- Value and Limitations of Existing Scores for the Assessment of Cardiovascular RiskJACC, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Role of Reticulated Platelets and Platelet Size Heterogeneity on Platelet Activity After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery DiseaseJACC, 2008
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statinsTrials, 2007
- A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in WomenNew England Journal of Medicine, 2005
- Reticulated platelets in acute coronary syndrome: A marker of platelet activityJACC, 2004
- Final Report on the Aspirin Component of the Ongoing Physicians' Health StudyNew England Journal of Medicine, 1989